What changed in this filing

/stocks — the workspaceLOADING

Item 5. Other Information

2023-11-13 compared with 2023-08-11 · 24 added, 23 removed, 28 unchanged (63% of the section changed)

2 unchanged sentences

DESCRIPTION OF DOCUMENT

Amended and Restated Certificate of Incorporation of the Registrant (incorporated by reference to Appendix G to the

Registrant’s Definitive Proxy Statement on Schedule 14A, filed on April 29, 2005).

Certificate of Amendment of Amended and Restated Certificate of Incorporation of the Registrant (incorporated by reference

to Exhibit 3.1 to the Registrant’s Current Report on Form 8-K, filed on May 5, 2017).

Certificate of Amendment of Amended and Restated Certificate of Incorporation of the Registrant (incorporated by reference

to Exhibit 3.1 to the Registrant’s Current Report on Form 8-K, filed on August 30, 2018).

Certificate of Amendment of Amended and Restated Certificate of Incorporation of the Registrant (incorporated by reference

to Exhibit 3.1 to the Registrant’s Current Report on Form 8-K, filed on April 12, 2019).

Amended and Restated Certificate of Incorporation of the Registrant (incorporated by reference to Appendix G to

the Registrant’s Definitive Proxy Statement on Schedule 14A, filed on April 29, 2005).

Certificate of Amendment of Amended and Restated Certificate of Incorporation of the Registrant (incorporated by

reference to Exhibit 3.1 to the Registrant’s Current Report on Form 8-K, filed on May 5, 2017).

Certificate of Amendment of Amended and Restated Certificate of Incorporation of the Registrant (incorporated by

reference to Exhibit 3.1 to the Registrant’s Current Report on Form 8-K, filed on August 30, 2018).

Certificate of Amendment of Amended and Restated Certificate of Incorporation of the Registrant (incorporated by

reference to Exhibit 3.1 to the Registrant’s Current Report on Form 8-K, filed on April 12, 2019).

Certificate of Amendment of Amended and Restated Certificate of Incorporation (incorporated by reference to

4 unchanged sentences

Registrant’s Current Report on Form 8-K, filed on November 6, 2020).

First Amendment to Second Amended and Restated Bylaws of the Registrant (incorporated by reference to Exhibit

3.1 to the Registrant’s Current Report on Form 8-K filed on June 10, 2022).

Second Amendment to Second Amended and Restated Bylaws of the Registrant (incorporated by reference to Exhibit

3.1 to the Registrant’s Current Report on Form 8-K filed on June 17, 2022).

Third Amendment to Second Amended and Restated Bylaws of the Registrant (incorporated by reference to Exhibit

3.1 to the Registrant’s Current Report on Form 8-K filed on June 2, 2023).

Interim President and CEO Consulting Letter Agreement by and between Ocuphire Pharma, Inc.

Rodgers, dated April 20, 2023 (incorporated by reference to Exhibit 10.1 to the Registrant’s Quarterly Report on Form 10-Q filed on May 15, 2023).

Second Amended and Restated Non-Employee Director Compensation Policy (incorporated by reference to Exhibit

10.2 to the Registrant’s Quarterly Report on Form 10-Q filed on May 15, 2023).

Separation and Release Agreement by and between Ocuphire Pharma, Inc.

and Mina Sooch, dated June 8, 2023.

First Amendment to Second Amended and Restated Bylaws of the Registrant (incorporated by reference to

Exhibit 3.1 to the Registrant’s Current Report on Form 8-K filed on June 10, 2022).

Second Amendment to Second Amended and Restated Bylaws of the Registrant (incorporated by reference to

Exhibit 3.1 to the Registrant’s Current Report on Form 8-K filed on June 17, 2022).

Third Amendment to Second Amended and Restated Bylaws of the Registrant (incorporated by reference to

Exhibit 3.1 to the Registrant’s Current Report on Form 8-K filed on June 2, 2023).

Purchase Agreement, dated as of August 10, 2023, by and between

Ocuphire Pharma, Inc.

and Lincoln Park Capital Fund, LLC (incorporated by reference to Exhibit 10.1 to the Registrant’s Current Report on Form 8-K, filed on August 11, 2023).

Registration Rights Agreement, dated as of August 10, 2023, by

and between Ocuphire Pharma, Inc.

and Lincoln Park Capital Fund, LLC (incorporated by reference to Exhibit 10.2 to the Registrant’s Current Report on Form 8-K, filed on August 11, 2023).

Certification of Principal Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.

12 unchanged sentences

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this Report to be signed on its behalf by the undersigned thereunto duly authorized.

August 11, 2023

November 13, 2023

Ocuphire Pharma, Inc.

/s/ Richard J.

Interim Chief Executive Officer

/s/ George Magrath

George Magrath

Chief Executive Officer

(Principal Executive Officer)

3 unchanged sentences

Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.

What changed 10-Q

Item 5. Other Information